Anzeige
Meldung des Tages: Milliarden aus Washington? Dieser kritische Rohstoff könnte der nächste Profiteur sein

Novartis Aktie (ADR) News

Aktie
WKN:  907122 ISIN:  US66987V1098 US-Symbol:  NVS Branche:  Pharmazeutika Land:  Schweiz
128,00 €
-0,50 €
-0,39%
03.02.26
Depot/Watchlist
Marktkapitalisierung *
231,76 Mrd. €
Streubesitz
92,87%
KGV
15,53
Dividende
3,87 $
Dividendenrendite
2,81%
Faktor
1
Originalaktie
CH0012005267

Novartis Aktie (ADR) News

27.10.25 - PR Newswire
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology PR Newswire
27.10.25 - PR Newswire
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology PR Newswire
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
15.10.25 - PR Newswire
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
Next-​Generation Targeted Therapies Reshape Precision Oncology Landscape PR Newswire
30.09.25 - PR Newswire
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) PR Newswire
03.09.25 - PR Newswire
Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases
Argo Biopharma Announces Multi-​Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases PR Newswire
11.08.25 - PR Newswire
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease PR Newswire
31.07.25 - PR Newswire
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Novartis twice-​yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-​line use PR Newswire
03.07.25 - PR Newswire
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA) PR Newswire
20.06.25 - PR Newswire
NYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth
NYSE Content Advisory: Pre-​Market update + Wall Street reopens after Juneteenth PR Newswire
20.06.25 - PR Newswire
NYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth
NYSE Content Advisory: Pre-​Market update + Wall Street reopens after Juneteenth PR Newswire
02.04.25 - PR Newswire
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA ...
20.03.25 - PR Newswire
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) PR Newswire
28.02.25 - PR Newswire
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) PR Newswire
19.02.25 - PR Newswire
CIBC introduces additional European Canadian Depositary Receipts ("CDRs")
CIBC introduces additional European Canadian Depositary Receipts ("CDRs") Canada NewsWire
02.12.24 - PR Newswire
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program PR Newswire
18.11.24 - PR Newswire
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate
Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate PR Newswire
25.05.24 - PR Newswire
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio PR Newswire
25.05.24 - PR Newswire
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. ...
15.04.24 - PR Newswire
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy ...

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »